SAB and DoD advance therapeutic drug candidate for Covid-19

SAB
SAB Biotherapeutics has won an expanded scope on its Rapid Response contract for its new therapeutic drug candidate to treat Covid-19 pandemic. Credit: SAB Biotherapeutics.